Insulin Resistance Linked to Risk for More Than 30 Diseases
By Elana Gotkine HealthDay Reporter
MONDAY, Sept. 9, 2024 -- Insulin resistance (IR) is associated with multiple systemic diseases, according a study presented at the annual meeting of the European Association for the Study of Diabetes, held from Sept. 9 to 13 in Madrid.
Jing Wu and Y. Song, from the Cheeloo College of Medicine at Shandong University in Jinan, China, explored the correlation between IR and systemic diseases using data from the U.K. Biobank, which recruited more than 500,000 participants aged 40 to 69 years. The degree of IR was measured using the triglyceride-glucose index and triglyceride/high-density lipoprotein cholesterol ratio.
The researchers identified a correlation between IR and 31 diseases (26 positive and five negative correlations) during a median follow-up of 13 years, and for all-cause mortality among women. Strong associations were seen for IR with diabetes, gout, disorders of lipoprotein metabolism, and other lipidemias. A novel finding of an association between IR and diseases such as gout, Parkinson disease, and sciatica was seen.
"We have shown that by assessing the degree of insulin resistance, it is possible to identify individuals who are at risk of developing obesity, hypertension, heart disease, gout, sciatica, and some other diseases," Wu said in a statement. "This provides a basis for early intervention measures to reduce the risk of disease and also offers new ideas for disease prevention and treatment."
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted September 2024
Read this next
Few Adolescents With Obesity Prescribed Obesity Medications
FRIDAY, June 13, 2025 -- Despite an increase in the prevalence of prescribing, only 0.5 percent of U.S. adolescents with obesity were prescribed an obesity medication in 2023...
Real-World Weight Loss With Semaglutide, Tirzepatide Less Than That Seen in Clinical Trials
THURSDAY, June 12, 2025 -- For patients with obesity initiating pharmacotherapy with semaglutide or tirzepatide, weight loss at one year is 8.7 percent on average, which is lower...
Adherence to Healthy Diet Improves Cardiometabolic Risk, Even Without Weight Loss
WEDNESDAY, June 11, 2025 -- A healthy diet improves cardiometabolic risk factors, even if not associated with weight loss (WL), according to a study published online June 5...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.